In a drug discovery career spanning more than two decades, Alex Lugovskoy has seen a lot of antibodies come and go. The vast majority of them work by inhibiting a cellular function. Lugovskoy, now the ...
WATERTOWN, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe ...
CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched today with $128 ...
Joel Levinson was in his second year of architecture studies at the University of Pennsylvania when he overheard two students speaking as if they were up to no good. These being fellow building buffs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results